Sanofi, Alnylam Q3 Reports Hint at Early Pipeline Impacts from IRA

Sanofi, Alnylam Q3 Reports Hint at Early Pipeline Impacts from IRA

Source: 
BioSpace
snippet: 

The implications of the Inflation Reduction Act of 2022 (IRA), which is aimed at lowering the price of prescription drugs, are already reverberating across biopharma pipelines as companies hint at – or explicitly state – their impacts.